Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017 (2017), Article ID 3098542, 9 pages
https://doi.org/10.1155/2017/3098542
Research Article

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients

1Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
2Department of Gynecologic Oncology, Institute for Cancer Genetics and Informatics and University of Oslo, Oslo, Norway
3MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK
4DOCs International, Buckinghamshire, UK
5Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
6Department of Medical Sciences, Medical School, University of Girona, Girona, Spain
7Medical Oncology, Royal Prince Alfred Hospital and Concord Repatriation General Hospital and Chris O’Brien Lifehouse, Sydney, NSW, Australia
8Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

Correspondence should be addressed to Ã…slaug Helland

Received 14 November 2016; Accepted 11 January 2017; Published 15 February 2017

Academic Editor: Ines Zidi

Copyright © 2017 Ann Rita Halvorsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Ovarian cancer patients are recognized with poor prognosis. This study aimed to identify microRNAs in plasma for predicting response to treatment and outcome. We have investigated microRNAs in plasma from ovarian cancer patients enrolled in a large multicenter study (ICON7), investigating the effect of adding bevacizumab to standard chemotherapy in patients diagnosed with epithelial ovarian cancer. Patients with different histology, grade, and FIGO stages were included () in this study. Screening of 754 unique microRNAs was performed in the discovery phase () using TaqMan Low Density Arrays. The results were validated using single assays and RT-qPCR. Low levels of miR-200b, miR-1274A , and miR-141 were significantly associated with better survival, confirmed with log-rank test in the validation set. The level of miR-1274A correlated with outcome was especially pronounced in the high-grade serous tumors. Interestingly, low level of miR-200c was associated with 5-month prolongation of PFS when treated with bevacizumab compared to standard chemotherapy. We found prognostic significance of miR-200b, miR-141, and miR-1274A in all histological types, where miR-1274A may be a specific marker in high-grade serous tumors. The level of miR-200c may be predictive of effect of treatment with bevacizumab. However, this needs further validation.